Glatiramer acetate for multiple sclerosis: A comprehensive review of mechanisms and clinical efficacy

Marina Zvartau-Hind, Christina Caon, Rana Zabad, Alexandros Tselis, Robert Lisak, Omar Khan

Research output: Contribution to journalReview article

3 Citations (Scopus)

Abstract

The 'Decade of the Brain' (1990-2000) saw unprecedented advances in neurosciences including multiple sclerosis. It could have not been more aptly named, as it produced a shift in the paradigm of multiple sclerosis management, making multiple sclerosis a treatable disorder with the availability of several therapeutic options. For a chronic progressive neurological disorder like multiple sclerosis, this change in the understanding and treatment touched the lives of hundreds of thousands of patients worldwide and many more who provided care and counsel as family and friends. Of the four agents available for the treatment of the most common type of multiple sclerosis - relapsing-remitting - three are β-interferons and one is a noninterferon polypeptide of four amino acids (glatiramer acetate) with a distinct immunomodulating profile. Glatiramer acetate is now approved and available in North America, Europe and many other countries. It has been tested in pivotal trials as well as long term extension trials for almost 10 years (8 years published) providing remarkable evidence of efficacy and safety. This review will highlight the immune mechanisms and clinical data reported with glatiramer acetate in multiple sclerosis over the past three decades.

Original languageEnglish (US)
Pages (from-to)285-294
Number of pages10
JournalExpert Review of Neurotherapeutics
Volume2
Issue number3
DOIs
StatePublished - Jun 24 2002

Fingerprint

Multiple Sclerosis
Relapsing-Remitting Multiple Sclerosis
Neurosciences
North America
Nervous System Diseases
Interferons
Therapeutics
Glatiramer Acetate
Safety
Amino Acids
Peptides
Brain

Keywords

  • Clinical trials
  • Copaxone
  • Copolymer 1
  • Glatiramer acetate
  • Multiple sclerosis
  • Relapsing-remitting

ASJC Scopus subject areas

  • Neuroscience(all)
  • Clinical Neurology
  • Pharmacology (medical)

Cite this

Glatiramer acetate for multiple sclerosis : A comprehensive review of mechanisms and clinical efficacy. / Zvartau-Hind, Marina; Caon, Christina; Zabad, Rana; Tselis, Alexandros; Lisak, Robert; Khan, Omar.

In: Expert Review of Neurotherapeutics, Vol. 2, No. 3, 24.06.2002, p. 285-294.

Research output: Contribution to journalReview article

Zvartau-Hind, Marina ; Caon, Christina ; Zabad, Rana ; Tselis, Alexandros ; Lisak, Robert ; Khan, Omar. / Glatiramer acetate for multiple sclerosis : A comprehensive review of mechanisms and clinical efficacy. In: Expert Review of Neurotherapeutics. 2002 ; Vol. 2, No. 3. pp. 285-294.
@article{540b0e4ad3854392be9de60d2c879680,
title = "Glatiramer acetate for multiple sclerosis: A comprehensive review of mechanisms and clinical efficacy",
abstract = "The 'Decade of the Brain' (1990-2000) saw unprecedented advances in neurosciences including multiple sclerosis. It could have not been more aptly named, as it produced a shift in the paradigm of multiple sclerosis management, making multiple sclerosis a treatable disorder with the availability of several therapeutic options. For a chronic progressive neurological disorder like multiple sclerosis, this change in the understanding and treatment touched the lives of hundreds of thousands of patients worldwide and many more who provided care and counsel as family and friends. Of the four agents available for the treatment of the most common type of multiple sclerosis - relapsing-remitting - three are β-interferons and one is a noninterferon polypeptide of four amino acids (glatiramer acetate) with a distinct immunomodulating profile. Glatiramer acetate is now approved and available in North America, Europe and many other countries. It has been tested in pivotal trials as well as long term extension trials for almost 10 years (8 years published) providing remarkable evidence of efficacy and safety. This review will highlight the immune mechanisms and clinical data reported with glatiramer acetate in multiple sclerosis over the past three decades.",
keywords = "Clinical trials, Copaxone, Copolymer 1, Glatiramer acetate, Multiple sclerosis, Relapsing-remitting",
author = "Marina Zvartau-Hind and Christina Caon and Rana Zabad and Alexandros Tselis and Robert Lisak and Omar Khan",
year = "2002",
month = "6",
day = "24",
doi = "10.1586/14737175.2.3.285",
language = "English (US)",
volume = "2",
pages = "285--294",
journal = "Expert Review of Neurotherapeutics",
issn = "1473-7175",
publisher = "Expert Reviews Ltd.",
number = "3",

}

TY - JOUR

T1 - Glatiramer acetate for multiple sclerosis

T2 - A comprehensive review of mechanisms and clinical efficacy

AU - Zvartau-Hind, Marina

AU - Caon, Christina

AU - Zabad, Rana

AU - Tselis, Alexandros

AU - Lisak, Robert

AU - Khan, Omar

PY - 2002/6/24

Y1 - 2002/6/24

N2 - The 'Decade of the Brain' (1990-2000) saw unprecedented advances in neurosciences including multiple sclerosis. It could have not been more aptly named, as it produced a shift in the paradigm of multiple sclerosis management, making multiple sclerosis a treatable disorder with the availability of several therapeutic options. For a chronic progressive neurological disorder like multiple sclerosis, this change in the understanding and treatment touched the lives of hundreds of thousands of patients worldwide and many more who provided care and counsel as family and friends. Of the four agents available for the treatment of the most common type of multiple sclerosis - relapsing-remitting - three are β-interferons and one is a noninterferon polypeptide of four amino acids (glatiramer acetate) with a distinct immunomodulating profile. Glatiramer acetate is now approved and available in North America, Europe and many other countries. It has been tested in pivotal trials as well as long term extension trials for almost 10 years (8 years published) providing remarkable evidence of efficacy and safety. This review will highlight the immune mechanisms and clinical data reported with glatiramer acetate in multiple sclerosis over the past three decades.

AB - The 'Decade of the Brain' (1990-2000) saw unprecedented advances in neurosciences including multiple sclerosis. It could have not been more aptly named, as it produced a shift in the paradigm of multiple sclerosis management, making multiple sclerosis a treatable disorder with the availability of several therapeutic options. For a chronic progressive neurological disorder like multiple sclerosis, this change in the understanding and treatment touched the lives of hundreds of thousands of patients worldwide and many more who provided care and counsel as family and friends. Of the four agents available for the treatment of the most common type of multiple sclerosis - relapsing-remitting - three are β-interferons and one is a noninterferon polypeptide of four amino acids (glatiramer acetate) with a distinct immunomodulating profile. Glatiramer acetate is now approved and available in North America, Europe and many other countries. It has been tested in pivotal trials as well as long term extension trials for almost 10 years (8 years published) providing remarkable evidence of efficacy and safety. This review will highlight the immune mechanisms and clinical data reported with glatiramer acetate in multiple sclerosis over the past three decades.

KW - Clinical trials

KW - Copaxone

KW - Copolymer 1

KW - Glatiramer acetate

KW - Multiple sclerosis

KW - Relapsing-remitting

UR - http://www.scopus.com/inward/record.url?scp=0036283486&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036283486&partnerID=8YFLogxK

U2 - 10.1586/14737175.2.3.285

DO - 10.1586/14737175.2.3.285

M3 - Review article

C2 - 19810859

AN - SCOPUS:0036283486

VL - 2

SP - 285

EP - 294

JO - Expert Review of Neurotherapeutics

JF - Expert Review of Neurotherapeutics

SN - 1473-7175

IS - 3

ER -